The stock reaction may be muted due to the expected nature of the revenue decline and strong cash position. Traders should focus on upcoming clinical catalysts in 2026, particularly data readouts for IMA203CD8 and IMA402, which could drive sentiment despite current financial losses.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $10.15entry
- T+1 · 9mo ago −2.86%α −1.54% · $9.86
- T+5 · 8mo ago −7.29%α −5.05% · $9.41
- T+20 · 8mo ago +1.97%α +5.76% · $10.35
- T+60 · 6mo ago +9.75%α −1.55% · $11.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics reported full-year 2025 financial results with a significant revenue decline to $56.8 million and a net loss of $230.8 million, driven by the prior year's one-time collaboration revenue. The company maintains a strong cash position of $551.4 million, extending its runway into 2028, and continues to advance its PRAME-targeted oncology pipeline with key milestones expected in 2026 and 2027, including pivotal data readouts and BLA submission for anzu-cel in melanoma.
Key Financial Metrics
Key Facts
- Revenue declined to $56.8 million in 2025 from $183.1 million in 2024, primarily due to the absence of one-time collaboration revenue from Bristol Myers Squibb.
- Net loss was $230.8 million in 2025 compared to a net profit of $17.9 million in 2024.
- Cash and financial assets totaled $551.4 million as of December 31, 2025, following a $125 million public offering, supporting operations into 2028.
- Phase 3 SUPRAME trial for anzu-cel in melanoma remains on track with interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027.
- Multiple clinical data updates expected in 2026 for IMA203CD8 (ovarian cancer) and IMA402 (melanoma, gynecologic cancers), with combination trials planned.
Financial Impact
Revenue down $126.3 million YoY; net loss widened by $248.7 million; R&D spend increased to $216.0 million from $174.0 million.
Risk Factors
- High cash burn rate with R&D and G&A expenses increasing, though offset by strong cash reserves.
- Clinical trial delays or negative data in upcoming readouts could impact valuation, particularly for the pivotal SUPRAME trial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250021 |
Track record
23 reports on IMTX
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers